Tempest Therapeutics Overview
- Year Founded
-
2011
- Status
-
Public
- Employees
-
4
- Stock Symbol
-
TPST
- Investments
-
2
- Share Price
-
$0.29
- (As of Friday Closing)
Tempest Therapeutics General Information
Description
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.
Contact Information
Website
www.tempesttx.comCorporate Office
- 2000 Sierra Point Parkway
- Suite 400
- Brisbane, CA 94005
- United States
Corporate Office
- 2000 Sierra Point Parkway
- Suite 400
- Brisbane, CA 94005
- United States
Tempest Therapeutics Timeline
Tempest Therapeutics Stock Performance
As of 20-Nov-2026, Tempest Therapeutics’s stock price is $0.29. Its current market cap is $5.74M with 20M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.29 | $0.31 | $0.28 - $4.22 | $5.74M | 20M | 2.52M | -$3.16 |
Tempest Therapeutics Financials Summary
As of 30-Sep-2026, Tempest Therapeutics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 20,872 | 15,032 | 32,041 | 94,577 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (39,629) | (26,309) | (41,637) | (28,776) |
| Net Income | (40,590) | (26,262) | (41,843) | (29,491) |
| Total Assets | 8,761 | 16,931 | 41,488 | 51,603 |
| Total Debt | 7,258 | 8,141 | 15,365 | 20,661 |
Tempest Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Tempest Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Tempest Therapeutics Comparisons
Industry
Financing
Details
Tempest Therapeutics Competitors (4)
One of Tempest Therapeutics’s 4 competitors is Ayala Pharmaceuticals, a Corporation company based in Wilmington, DE.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Ayala Pharmaceuticals | Corporation | Wilmington, DE | ||||
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA | ||||
| Aura Biosciences | Formerly VC-backed | Boston, MA | ||||
| AVEO Oncology | Formerly VC-backed | Boston, MA |
Tempest Therapeutics Patents
Tempest Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026198803-A1 | Formulations of triazolone compounds and uses thereof | Pending | 20-Mar-2025 | ||
| WO-2026198779-A1 | Methods of making a ppar alpha antagonist | Pending | 20-Mar-2025 | ||
| WO-2025235527-A1 | Crystalline forms of a ppar alpha antagonist | Pending | 08-May-2024 | ||
| WO-2024102968-A1 | Uses of ep2/ep4 antagonist compounds for treating familial adenomatous polyposis (fap) | Inactive | 10-Nov-2022 | ||
| WO-2024102620-A2 | Triazolone compounds and uses thereof | Inactive | 09-Nov-2022 | A61K31/4196 |
Tempest Therapeutics Signals
Tempest Therapeutics Investments & Acquisitions (2)
Tempest Therapeutics’s most recent deal was a Corporate Asset Purchase with Factor Bioscience (Certain Dual-Targeting Chimeric Antigen Receptor (CAR)-T Programs). The deal was made on 04-Feb-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Factor Bioscience (Certain Dual-Targeting Chimeric Antigen Receptor (CAR)-T Programs) | 04-Feb-2026 | Corporate Asset Purchase | Drug Discovery | ||
| Millendo Therapeutics | 25-Jun-2021 | Merger/Acquisition | Biotechnology |
Tempest Therapeutics ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
Tempest Therapeutics FAQs
-
When was Tempest Therapeutics founded?
Tempest Therapeutics was founded in 2011.
-
Where is Tempest Therapeutics headquartered?
Tempest Therapeutics is headquartered in Brisbane, CA.
-
What is the size of Tempest Therapeutics?
Tempest Therapeutics has 4 total employees.
-
What industry is Tempest Therapeutics in?
Tempest Therapeutics’s primary industry is Drug Discovery.
-
Is Tempest Therapeutics a private or public company?
Tempest Therapeutics is a Public company.
-
What is Tempest Therapeutics’s stock symbol?
The ticker symbol for Tempest Therapeutics is TPST.
-
What is the current stock price of Tempest Therapeutics?
As of 20-Nov-2026 the stock price of Tempest Therapeutics is $0.29.
-
What is the current market cap of Tempest Therapeutics?
The current market capitalization of Tempest Therapeutics is $5.74M.
-
Who are Tempest Therapeutics’s competitors?
Ayala Pharmaceuticals, Inovio Pharmaceuticals, Aura Biosciences, and AVEO Oncology are competitors of Tempest Therapeutics.
-
What is Tempest Therapeutics’s annual earnings per share (EPS)?
Tempest Therapeutics’s EPS for 12 months was -$3.16.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process